Back to top

Image: Bigstock

Abeona Treats First Patient in Pivotal Gene Therapy Study

Read MoreHide Full Article

Abeona Therapeutics Inc. (ABEO - Free Report) announced that it has treated the first patient in the pivotal phase III study — VIITAL — evaluating its lead pipeline candidate, EB-101, in patients with recessive dystrophic epidermolysis bullosa (“RDEB”). The rare connective tissue disorder, RDEB, is characterized by severe skin wounds and can lead to systemic complications.

The study is being conducted by investigators at Stanford University Medical Center and enrollment in it is ongoing.

Currently, there are no FDA-approved therapies for treating RDEB. A successful development of the gene-corrected cell therapy candidate, EB-101 will be a major boost for the clinical-stage pharma company.

Please note that the company has successfully completed a phase I/II study on EB-101 in RDEB patients. Data from the study showed that treatment with the candidate resulted in sustained and durable wound healing. It also had a favorable safety profile.

Shares of Abeona have lost 37.7% so far this year compared with the industry’s decline of 12.7%.

 

 

Apart from EB-101, the company has two other clinical-stage pipeline candidates in its portfolio. The candidates — ABO-102 and ABO-101 — are adeno-associated virus (“AAV”)-based gene therapies, which are being developed for treating Sanfilippo syndrome type A and Sanfilippo syndrome type B, respectively.

The company is also planning to initiate a phase I/II study to evaluate pre-clinical AAV-based gene therapy candidate, ABO-202 in patients with CLN1 disease soon. An investigational new drug application to support the initiation of the study was approved by the FDA in May 2019.

Zacks Rank & Stocks to Consider

Abeona currently has Zacks Rank #3 (Hold) stock.

Some better-ranked stocks from the biotech sector include Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , MeiraGTx Holdings PLC (MGTX - Free Report) and Verona Pharma PLC (VRNA - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Regeneron’s earnings estimates for 2020 have gone up from $28.31 to $29.18 and from $28.93 to $30.97 for 2021 over the past 30 days. Regeneron’s stock has returned 31% so far in 2020.

MeiraGTx’s loss estimates for 2020 have narrowed from $2.41 to $2.06 and from $4.10 to $3.40 for 2021 over the past 30 days.

Verona’s loss estimates for 2020 have narrowed from $3.95 to $2.65 and from $3.96 to $2.59 for 2021 over the past 30 days.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Published in